Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

8.51

Margin Of Safety %

Put/Call OI Ratio

0.14

EPS Next Q Diff

0.02

EPS Last/This Y

-0.02

EPS This/Next Y

1.25

Price

2.09

Target Price

8.29

Analyst Recom

1

Performance Q

-64.95

Relative Volume

0.74

Beta

0.71

Ticker: ALDX



22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-04-14ALDX2.120.250.1946690
2025-04-15ALDX2.20.250.0447010
2025-04-16ALDX2.020.250.4947121
2025-04-17ALDX2.180.170.3144111
2025-04-18ALDX2.190.170.3144111
2025-04-21ALDX2.240.180.0229676
2025-04-22ALDX2.330.170.0729623
2025-04-23ALDX2.410.170.0329610
2025-04-24ALDX2.640.170.4229725
2025-04-25ALDX2.660.169027903143520.1687763713080229788
2025-04-28ALDX2.760.171590909090910.2067901234567929899
2025-04-29ALDX2.690.170.0029845
2025-04-30ALDX2.650.170.0029902
2025-05-01ALDX2.690.170.0030025
2025-05-02ALDX2.80.170.0430453
2025-05-05ALDX2.690.170.0230996
2025-05-06ALDX2.10.160.0332779
2025-05-07ALDX2.010.150.0033195
2025-05-08ALDX2.150.140.0134342
2025-05-09ALDX2.180.140.0334377
2025-05-12ALDX2.20.140.8034420
2025-05-13ALDX2.080.140.0134426
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1



22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-04-14ALDX2.12-74.3- -0.46
2025-04-15ALDX2.20-74.3- -0.46
2025-04-16ALDX2.02-74.3- -0.46
2025-04-17ALDX2.19-74.3- -0.46
2025-04-18ALDX2.19-74.3- -0.96
2025-04-21ALDX2.25-74.3- -0.96
2025-04-22ALDX2.32-74.3- -0.96
2025-04-23ALDX2.42-74.3- -0.96
2025-04-24ALDX2.64-74.3- -0.96
2025-04-25ALDX2.66-74.3- -0.96
2025-04-28ALDX2.76-74.3- -0.96
2025-04-29ALDX2.69-74.3- -0.96
2025-04-30ALDX2.64-74.3- -0.96
2025-05-01ALDX2.68-74.3- -0.96
2025-05-02ALDX2.81-74.3- -0.96
2025-05-05ALDX2.68-74.3- -0.96
2025-05-06ALDX2.10-74.3- -0.96
2025-05-07ALDX2.01-74.3- -0.96
2025-05-08ALDX2.15-74.3- -0.96
2025-05-09ALDX2.19-74.3- -0.96
2025-05-12ALDX2.21-74.3- -0.96
2025-05-13ALDX2.09-74.3- -0.96
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1



22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-04-14ALDX-66.25-11.316.12
2025-04-15ALDX-66.25-11.316.12
2025-04-16ALDX-66.25-11.316.12
2025-04-17ALDX-66.25-11.316.12
2025-04-18ALDX-66.25-11.316.12
2025-04-21ALDX-66.25-11.356.12
2025-04-22ALDX-66.26-11.356.12
2025-04-23ALDX-66.26-11.356.12
2025-04-24ALDX-66.26-11.356.12
2025-04-25ALDX-66.26-11.356.12
2025-04-28ALDX-66.26-11.747.43
2025-04-29ALDX-66.26-11.747.43
2025-04-30ALDX-66.26-11.747.43
2025-05-01ALDX-66.26-11.747.43
2025-05-02ALDX-66.19-11.747.43
2025-05-05ALDX-66.26-12.107.41
2025-05-06ALDX-66.26-12.107.41
2025-05-07ALDX-66.19-12.107.41
2025-05-08ALDX-66.19-12.107.41
2025-05-09ALDX-66.19-12.107.41
2025-05-12ALDX-66.19-13.128.51
2025-05-13ALDX-66.19-13.128.51
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS​

-0.27

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

-0.25

Insider Transactions

-66.19

Institutional Transactions

-13.12

Beta

0.71

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

13

Growth Score

26

Sentiment Score

40

Actual DrawDown %

86.9

Max Drawdown 5-Year %

-90.4

Target Price

8.29

P/E

Forward P/E

14.05

PEG

P/S

P/B

1.75

P/Free Cash Flow

EPS

-0.94

Average EPS Est. Cur. Y​

-0.96

EPS Next Y. (Est.)

0.29

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.74

Return on Equity vs Sector %

-102.3

Return on Equity vs Industry %

-85.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.5

EBIT Estimation

Aldeyra Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 9
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
stock quote shares ALDX – Aldeyra Therapeutics, Inc. Stock Price stock today
news today ALDX – Aldeyra Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALDX – Aldeyra Therapeutics, Inc. yahoo finance google finance
stock history ALDX – Aldeyra Therapeutics, Inc. invest stock market
stock prices ALDX premarket after hours
ticker ALDX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Facebook-f Twitter Tiktok Instagram Youtube

Get Started

About